TY - JOUR
T1 - Antibiotic resistance in the patient with cancer
T2 - Escalating challenges and paths forward
AU - Nanayakkara, Amila K.
AU - Boucher, Helen W.
AU - Fowler, Vance G.
AU - Jezek, Amanda
AU - Outterson, Kevin
AU - Greenberg, David E.
N1 - Funding Information:
No specific funding was disclosed. Helen W. Boucher reports honoraria as editor of , , and the Sanford Guide. Vance G. Fowler, Jr, reports personal fees from Novartis, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Company, Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, and Aridi; grants from the National Institutes of Health, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Basilea, and Janssen; royalties from UpToDate; stock options in Valanbio; a patent pending in sepsis diagnostics; educational fees from Green Cross, Cubist, Cerexa, Durata, Theravance, and Debiopharm; and an editor's stipend from the Infectious Diseases Society of America all outside the submitted work. Kevin Outterson reports grants from the US Biomedical Advanced Research and Development Authority, the Wellcome Trust (United Kingdom), the Global Antimicrobial Resistance Innovation Fund (United Kingdom), the Federal Ministry of Education and Research (Germany), and the Bill and Melinda Gates Foundation outside the submitted work. David E. Greenberg reports grants from the National Institutes of Health, the US Department of Defense, and Shionogi; personal fees from MDC Associates; patents relating to antisense molecules and alternating magnetic fields; and serves as the Chief Medical Officer and founder of Solenic Medical, for which he has stock options and receives consultant fees, all outside the submitted work. Amila K. Nanayakkara and Amanda Jezek had no disclosures. DISCLOSURES: Infectious Diseases Clinics of North America Antimicrobial Agents and Chemotherapy
Publisher Copyright:
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Infection is the second leading cause of death in patients with cancer. Loss of efficacy in antibiotics due to antibiotic resistance in bacteria is an urgent threat against the continuing success of cancer therapy. In this review, the authors focus on recent updates on the impact of antibiotic resistance in the cancer setting, particularly on the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.). This review highlights the health and financial impact of antibiotic resistance in patients with cancer. Furthermore, the authors recommend measures to control the emergence of antibiotic resistance, highlighting the risk factors associated with cancer care. A lack of data in the etiology of infections, specifically in oncology patients in United States, is identified as a concern, and the authors advocate for a centralized and specialized surveillance system for patients with cancer to predict and prevent the emergence of antibiotic resistance. Finding better ways to predict, prevent, and treat antibiotic-resistant infections will have a major positive impact on the care of those with cancer.
AB - Infection is the second leading cause of death in patients with cancer. Loss of efficacy in antibiotics due to antibiotic resistance in bacteria is an urgent threat against the continuing success of cancer therapy. In this review, the authors focus on recent updates on the impact of antibiotic resistance in the cancer setting, particularly on the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.). This review highlights the health and financial impact of antibiotic resistance in patients with cancer. Furthermore, the authors recommend measures to control the emergence of antibiotic resistance, highlighting the risk factors associated with cancer care. A lack of data in the etiology of infections, specifically in oncology patients in United States, is identified as a concern, and the authors advocate for a centralized and specialized surveillance system for patients with cancer to predict and prevent the emergence of antibiotic resistance. Finding better ways to predict, prevent, and treat antibiotic-resistant infections will have a major positive impact on the care of those with cancer.
KW - antibiotic resistance
KW - antibiotics
KW - bacterial infections
KW - cancer
UR - http://www.scopus.com/inward/record.url?scp=85115255731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115255731&partnerID=8YFLogxK
U2 - 10.3322/caac.21697
DO - 10.3322/caac.21697
M3 - Review article
C2 - 34546590
AN - SCOPUS:85115255731
SN - 0007-9235
VL - 71
SP - 488
EP - 504
JO - CA Cancer Journal for Clinicians
JF - CA Cancer Journal for Clinicians
IS - 6
ER -